Molecular Templates, Inc. (MTEM): Price and Financial Metrics
MTEM Stock Summary
- Of note is the ratio of Molecular Templates Inc's sales and general administrative expense to its total operating expenses; only 10.83% of US stocks have a lower such ratio.
- With a price/sales ratio of 25.94, Molecular Templates Inc has a higher such ratio than 91.49% of stocks in our set.
- With a year-over-year growth in debt of 85.6%, Molecular Templates Inc's debt growth rate surpasses 88.62% of about US stocks.
- Stocks that are quantitatively similar to MTEM, based on their financial statements, market capitalization, and price volatility, are CRBP, FIXX, NTLA, VYGR, and CTMX.
- MTEM's SEC filings can be seen here. And to visit Molecular Templates Inc's official web site, go to www.mtem.com.
MTEM Stock Price Chart Interactive Chart >
MTEM Price/Volume Stats
| Current price | $8.93 | 52-week high | $18.44 |
| Prev. close | $8.72 | 52-week low | $7.51 |
| Day low | $8.64 | Volume | 431,200 |
| Day high | $9.07 | Avg. volume | 463,786 |
| 50-day MA | $10.92 | Dividend yield | N/A |
| 200-day MA | $10.88 | Market Cap | 500.54M |
Molecular Templates, Inc. (MTEM) Company Bio
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is based in Austin, Texas.
Latest MTEM News From Around the Web
Below are the latest news stories about Molecular Templates Inc that investors may wish to consider to help them evaluate MTEM as an investment opportunity.
Molecular Templates has a ‘unique’ platform in oncology: BofAMolecular Templates ([[MTEM]] +9.5%) has posted its best one-day gain since December after Bank of America initiated the coverage on the stock with a buy rating and a price target of $12.00 per share indicating a premium of ~50.8% to yesterday’s close.The firm calls the company’s engineered toxin body (“ETB”)... |
Insider Buying Of Molecular Templates Stock Corresponds With Analyst RatingsClinical-stage biopharmaceutical company Molecular Templates (MTEM) has seen multiple informed key insider purchases over the past few weeks. Whenever insiders such as top management, board members, or significant stake owners add to their holdings, it could be a very positive signal for retail investors. While all information within companies may not be public, regulations stipulate the timely disclosure of trades that are executed by corporate insiders. This often provides retail investors with important insights into the financial health of the company. |
Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting IPosters will feature data on MT-5111 (targeting HER2), MT-6402 (targeting PD-L1) and a novel CTLA-4-targeted ETBAUSTIN, Texas, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported that three posters featuring data on its pipeline programs and technology platform will be presented at the AACR Virtual Annual Meeting I, taking place April 10-15, 2021. Title:Phase 1 Study of the Novel Immunotoxin MT-5111 in Patients with HER2+ TumorsAuthors:Zev A. Wainberg, MD; Monica M. Mita, MD; Minal A. Barve, MD; Erika P. Hamilton, MD; Andrew J. Brenner, MD, PhD; Frances ... |
Molecular Templates drops 25% on discontinuation of lead asset in lymphomaShares of Molecular Templates (MTEM) are down 25% after the company announced it was discontinuing development of its lead asset, MT-3724, in diffuse large B-cell lymphoma.MT-3724 is an immunotoxin known as an engineered toxin body ("ETB") that targets CD20.The candidate was first under under a partial clinical hold, and then a full... |
Molecular Templates Stock Falls After It Stops MT-3724 Development In Hematological MalignanciesMolecular Templates Inc (NASDAQ: MTEM ) has decided to discontinue the development of MT-3724, its only first-generation engineered toxin bodies (ETB), and focus its resources on the development of next-generation ETBs. In November last year, FDA instituted a partial clinical hold on Phase 2 MT-3724 monotherapy study following a treatment-related fatality in one subject who … Full story available on Benzinga.com |
MTEM Price Returns
| 1-mo | -21.94% |
| 3-mo | -25.89% |
| 6-mo | -7.65% |
| 1-year | -46.14% |
| 3-year | 8.77% |
| 5-year | 84.50% |
| YTD | -4.90% |
| 2020 | -32.86% |
| 2019 | 246.16% |
| 2018 | -59.68% |
| 2017 | 107.02% |
| 2016 | -8.33% |
Continue Researching MTEM
Want to see what other sources are saying about Molecular Templates Inc's financials and stock price? Try the links below:Molecular Templates Inc (MTEM) Stock Price | Nasdaq
Molecular Templates Inc (MTEM) Stock Quote, History and News - Yahoo Finance
Molecular Templates Inc (MTEM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...